- Horizon Therapeutics reported positive topline results from the MIRROR study of Krystexxa in combination with methotrexate.
- The results pave the ways for the sBLA submission in Q1 2022, approval should allow the company to aggressively promote the combination which is currently used off-label.
- MIRROR is an important step for Horizon's gout franchise, but there is more to come from Krystexxa in the near/medium term and from the company's expanding preclinical pipeline.
- Investors are underestimating the long-term potential of Horizon's gout franchise.
For further details see:
Positive MIRROR Results An Important Step For Horizon Therapeutics' Gout Franchise